On December 20th, 2023, the European Patent Office published the mention of the grant of the European Patent for the invention ‘PYRIDIN-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO INTERLEUKIN 1 BETA.’ This patent grants Allinky exclusive rights to the invention within the European market, further enhancing our competitive advantage and opening up new opportunities for growth and collaboration.
The clinical evaluation of this candidate will open new avenues in the treatment of diseases where IL-1β plays an essential role, such as IPF or NASH, two diseases for which there is currently no cure.